세계의 저분자 이노베이터 CDMO 시장 : 시장 규모, 점유율 및 동향 분석(제품별, 단계 유형별, 치료 영역별, 고객 유형별, 지역별), 부문별 예측(2025-2033년)

Small Molecule Innovator CDMO Market Summary

The global small molecule innovator CDMO market size was estimated at USD 41.39 billion in 2024 and is projected to reach USD 69.38 billion by 2033, growing at a CAGR of 6.07% from 2025 to 2033. The growth of the market is due to the increasing outsourcing of drug development and manufacturing by pharmaceutical innovators, particularly in the small molecule space.

As drug pipelines become more complex and regulatory scrutiny tightens, pharmaceutical companies are relying more on CDMOs to provide specialized services such as API synthesis, formulation development, and clinical-scale production. The market is driven by a growing reliance on outsourcing among pharmaceutical companies aiming to streamline operations, reduce internal manufacturing burdens, and accelerate drug development timelines. Innovator companies, especially emerging biotechs with limited infrastructure, increasingly turn to CDMOs for specialized services ranging from early-phase development to commercial manufacturing. This trend is reinforced by the complexity of regulatory compliance, the need for advanced containment facilities for potent APIs, and the high costs associated with maintaining in-house capabilities. The rise in clinical trials and new molecular entities (NMEs) targeting oncology, infectious diseases, and rare disorders is pushing demand for CDMOs that offer high-quality API production, analytical testing, and formulation development expertise under cGMP conditions.

Global Small Molecule Innovator CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule innovator CDMO market report based on product, stage type, customer type, therapeutic area, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule API
• Small Molecule Drug Product
  • Oral Solid Dose
  • Semi-Solid Dose
  • Liquid Dose
  • Others
• Stage Type Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical
• Clinical
  • Phase I
  • Small
  • Medium
  • Large
  • Phase II
  • Small
  • Medium
  • Large
  • Phase III
  • Small
  • Medium
  • Large
• Commercial
• Customer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
  • Small
  • Medium
  • Large
• Biotechnology
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Oncology
• Respiratory Disorders
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Small Molecule Innovator CDMO Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Small Molecule Innovator CDMO Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Small Molecule Innovator CDMO Market: Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis

Chapter 4. Small Molecule Innovator CDMO Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Small Molecule Innovator CDMO Market Product Movement Analysis
• 4.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Small Molecule API
  • 4.4.1. Small Molecule API Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Small Molecule Drug Product
  • 4.5.1. Small Molecule Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.2. Oral Solid Dose
    • 4.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.3. Semi-Solid Dose
    • 4.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.4. Liquid Dose
    • 4.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD million)

Chapter 5. Small Molecule Innovator CDMO Market: Stage Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Small Molecule Innovator CDMO Market Stage Type Movement Analysis
• 5.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Stage Type, 2021 to 2033 (USD Million)
• 5.4. Preclinical
  • 5.4.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Clinical
  • 5.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Phase I
    • 5.5.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.2. Small
      • 5.5.2.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.3. Medium
      • 5.5.2.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.4. Large
      • 5.5.2.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 5.5.3. Phase II
    • 5.5.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.2. Small
      • 5.5.3.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.3. Medium
      • 5.5.3.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.4. Large
      • 5.5.3.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 5.5.4. Phase III
    • 5.5.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.2. Small
      • 5.5.4.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.3. Medium
      • 5.5.4.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.4. Large
      • 5.5.4.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 5.6. Commercial
  • 5.6.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule Innovator CDMO Market: Customer Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Small Molecule Innovator CDMO Market Customer Type Movement Analysis
• 6.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Customer Type, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical
  • 6.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Small
    • 6.4.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Medium
    • 6.4.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Large
    • 6.4.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biotechnology
  • 6.5.1. Biotechnology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule Innovator CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Small Molecule Innovator CDMO Market Therapeutic Area Movement Analysis
• 7.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 7.4. Cardiovascular diseases
  • 7.4.1. Cardiovascular diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Respiratory disorders
  • 7.6.1. Respiratory disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Neurology
  • 7.7.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Metabolic Disorders
  • 7.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Infectious Diseases
  • 7.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Small Molecule Innovator CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Small Molecule Innovator CDMO Market Share Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Piramal Pharma Solutions
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. CordenPharma International
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Wuxi AppTec
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Cambrex Corporation
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Recipharm AB
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Thermo Fisher Scientific, Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Lonza
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Catalent Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Siegfried Holding AG
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Boehringer Ingelheim
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Labcorp
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives